Activation of the cGAS-STING pathway in lung cancer radiotherapy has shown great antitumor potential by promoting the secretion of type I IFNs, significantly increasing the infiltration of CD + 8 T cells and effectively stimulating anti-tumor immune responses in the body. Here, STING1 is linked to lung carcinoma.